ProCE Banner Activity

RATIFY: Midostaurin Added to Standard Chemotherapy Prolongs OS in Patients With Newly Diagnosed FLT3-Mutated AML

Slideset Download
Conference Coverage
Midostaurin added to chemotherapy significantly improved survival vs placebo in patients with FLT3-mutated AML.

Released: December 11, 2015

Expiration: December 09, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen